Opendata, web and dolomites

MGLycan SIGNED

Targeting hMGL-GalNAc interactions to reverse immune suppression in cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MGLycan project word cloud

Explore the words cloud of the MGLycan project. It provides you a very rough idea of what is the project "MGLycan" about.

selective    clrs    tolerogenic    tumor    inhibitors    carbohydrates    interactions    apoptosis    alters    receptors    truncated    hallmarks    macrophage    despite    lectin    playing    evasion    tn    interaction    immunotherapy    mimetics    clr    immunosuppression    receptor    moieties    diverse    carbohydrate    poorly    thr    effector    overlooked    perceives    immature    binding    cells    antigens    aberrant    ligands    affinity    induction    limits    mostly    dendritic    multivalent    cell    tacas    secretion    clear    glycan    appearance    upregulated    human    mechanisms    terminal    accompanied    synthesis    immunosuppressive    facilitated    ing    galnac    antigen    prime    surface    toward    suppression    cytokine    mediated    interacts    hmgl    recognizes    serve    fact    glycosylation    vaccines    strategies    alpha    signaling    reverse    cancer    immune    mgl    galactose    proliferation    glycans    escape    mediate    macrophages    dcs    efficacy    ser    induce   

Project "MGLycan" data sheet

The following table provides information about the project.

Coordinator
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE 

Organization address
address: PASEO MIRAMON 182, PARQUE TECNOLOGICO DE SAN SEBASTIAN EDIFICIO EMPRESARIAL C
city: SAN SEBASTIAN
postcode: 20009
website: www.cicbiomagune.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 172˙932 €
 EC max contribution 172˙932 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE ES (SAN SEBASTIAN) coordinator 172˙932.00

Map

 Project objective

The appearance of aberrant glycans on the tumor cell surface is one of the emerging hallmarks of cancer. Tumor growth is accompanied by tumor evasion of the immune system which limits the efficacy of cancer vaccines. However, and despite the fact that aberrant tumor glycosylation alters how the immune system perceives the tumor and, can also induce immunosuppressive signaling through glycan-binding receptors, the role of tumor glycosylation in immune evasion has mostly been overlooked. It is clear that new strategies to avoid the immune escape mechanisms generated by tumor cells are required. The interaction between the immune system and Tumor-Associated Carbohydrates Antigens (TACAs) is facilitated by a diverse set of carbohydrate-binding receptors, as the C-type lectin receptors (CLRs) which mediate specific interactions with TACAs controlling many features of the immune response. The immune escape mechanisms generated by truncated O-glycans, such as Tn antigen (αGalNAc-Ser/Thr) are still poorly understood. Human macrophage galactose-type lectin (hMGL) is a CLR that recognizes terminal GalNAc moieties, and is, therefore, a prime receptor for the aberrant O-glycans in cancer. MGL is upregulated in tolerogenic and immature dendritic cells (DCs) and macrophages playing an important role in immunosuppression. It interacts with effector T-cells, resulting in reduced proliferation, cytokine secretion and induction of T-cell apoptosis. In this project, we propose the design and synthesis of multivalent MGL ligands mimetics with an improved affinity toward this receptor, that will serve as selective inhibitors to reverse GalNAc-mediated immune suppression for cancer immunotherapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MGLYCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MGLYCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

MathematicsAnalogies (2019)

Mathematics Analogies

Read More  

DiMaS (2019)

Retrospective genomic analyses of shortfin Mako shark (Isurus oxyrinchus) using DNA from archived jaws

Read More